Prelude Therapeutics(PRLD) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude's once daily, oral SMARCA2 degrader, PRT7732 is advancing rapidly, and an initial data update is anticipated in the second half of 2025 Current cash runway into the second quarter of 2026 with $103.1 ...